You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Secondary AML and VYXEOS downloads and resources

JazzCares enrollment form download

JazzCares enrollment form

The JazzCares program at Jazz Pharmaceuticals provides reimbursement and coverage information for your patients receiving VYXEOS

VYXEOS dosing and administration brochure download

VYXEOS dosing and administration brochure

Learn more about induction, consolidation, and outpatient administration with VYXEOS

VYXEOS patient brochure download

VYXEOS patient brochure

Provide your patients with information about their treatment with VYXEOS

VYXEOS preparation instructions download

VYXEOS preparation instructions

A quick reference of VYXEOS preparation instructions

Information about acute myeloid leukemia (AML)

The Leukemia & Lymphoma Society

www.lls.org

1-800-955-4572

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.